Sort   by:  
 Page size 
TranscriptomicsTherapeutic potential of a novel HSP90 Inhibitor, NXD30001, for Neurofibromatosis type 2
Purpose: The growth and survival of NF2-deficient cells are enhanced by the activation of multiple signaling pathways including ErbB2/IGF-1R/Met, PI3K/Akt, and Ras/Raf/Mek/Erk1/2. The ubiquitously expressed chaperone protein HSP90 is known to be essential for the stabilization of these signaling mol...
ORGANISM(S): Mus musculus 
2013-06-06 | E-GEOD-40187 | biostudies-arrayexpress
UnknownPatient-reported measures of tinnitus for individuals with neurofibromatosis type 2-related schwannomatosis: Recommendations for clinical trials.
Not available
S-EPMC10865763 | biostudies-literature
GenomicsNext generation sequencing of sporadic schwannomatosis samples
Schwannomatosis (MIM #162091) is characterized by the development of multiple schwannomas without vestibular nerve involvement (which is a characteristic of neurofibromatosis type 2 - NF2). In an effort to detect novel genetic alterations predisposing to schwannomatosis, we sequenced eight tumor-blo...
EGAS00001000767 | EGA
Unknown2016 Children's Tumor Foundation conference on neurofibromatosis type 1, neurofibromatosis type 2, and schwannomatosis.
Not available
S-EPMC5918269 | biostudies-literature
UnknownSimultaneous inhibition of PI3K and PAK in preclinical models of neurofibromatosis type 2-related schwannomatosis.
Not available
S-EPMC10959746 | biostudies-literature
UnknownPotential endpoints for assessment of bone health in persons with neurofibromatosis type 1.
Not available
S-EPMC10920397 | biostudies-literature
MetabolomicsRevealing Hidden Variables in DESI-based Spatial Metabolomics: Solvent Composition and Tissue Type as Critical Drivers
In the development of a desorption electrospray ionization (DESI) workflow for spatial metabolomics, we investigated the impact of two commonly used solvent systems, 90% acetonitrile (ACN) and 90% methanol (MeOH), on the spatial metabolomic profiling of multiple murine tissues. The performance of bo...
2026-09-11 | MTBLS14771 | MetaboLights
ProteomicsKinome profiling of Nf2-null murine Schwann cell line MS03 with defactinib and VS-4718
Patients with neurofibromatosis type 2-related schwannomatosis (NF2-SWN) develop hallmark tumors on their vestibular nerves, leading to hearing loss and numerous associated morbidities. Currently, there are no targeted therapeutic options for treating these tumors. In prior work, our group had ident...
ORGANISM(S): Mus musculus (Mouse) 
2025-09-17 | PXD060730 | Pride
Focal adhesion kinase inhibitor Neurofibromatosis type 2-related schwannomatosis Multiplexed kinase inhibitor beads Kinase inhibitor 
UnknownWithdrawal of bevacizumab is associated with rebound growth of vestibular schwannomas in neurofibromatosis type 2-related schwannomatosis patients.
Not available
S-EPMC10576512 | biostudies-literature
UnknownHistorical Development of Diagnostic Criteria for NF2-related Schwannomatosis.
Not available
S-EPMC11374461 | biostudies-literature
Sort   by:  
 Page size